Abstract:The disposition of morphine was investigated by means of radioimmunoassay after a single intravenous dose (10 milligrams per 70 kilograms) was administered to 10 adult normal male subjects who had not received other drugs for 2 weeks preceding the study. A multiphasic decline in serum concentrations of morphine occurred. Detectable blood concentrations of morphine, or of a metabolite, or of both persisted for 48 hours after a single intravenous dose.
“…From the studies of Spector and Vesell (Fig. I ) 20 and Brunk and Delle (Fig. 1), 2 the apparent volume of distribution (Vd) of morphine after parenteral administration to man can be esti- mated by extrapolation of the plasma decay curve from 1 to 6 hr to the zero time, multiplying this plasma concentration by 0.65 to obtain the free drug concentration, and dividing the dose by the free plasma morphine concentration.…”
The binding of morphine and phenytoin to plasma proteins was examined in healthy subjects and in patients with renal and hepatic failure. In the uremic patients without hepatic failure, morphine binding was dependent on the concentration of total serum proteins and albumin, but not the severity of renal failure as measured by creatinine clearance. Binding of phenytoin, however, was dependent on the degree of renal failure and albumin concentration, but not on total serum protein concentration. Renal transplant in 1 patient restored the binding of both drugs to a value within the normal range. The combination of hypoalbuminemia and hyperbilirubinemia resulted in the greatest impairment to binding for both drugs. It is concluded that patients with uremia, jaundice, hypoalbuminemia, particularly in combination, are sensitive to usual clinical doses of morphine, at least in part, because of decreased binding to plasma proteins.
“…From the studies of Spector and Vesell (Fig. I ) 20 and Brunk and Delle (Fig. 1), 2 the apparent volume of distribution (Vd) of morphine after parenteral administration to man can be esti- mated by extrapolation of the plasma decay curve from 1 to 6 hr to the zero time, multiplying this plasma concentration by 0.65 to obtain the free drug concentration, and dividing the dose by the free plasma morphine concentration.…”
The binding of morphine and phenytoin to plasma proteins was examined in healthy subjects and in patients with renal and hepatic failure. In the uremic patients without hepatic failure, morphine binding was dependent on the concentration of total serum proteins and albumin, but not the severity of renal failure as measured by creatinine clearance. Binding of phenytoin, however, was dependent on the degree of renal failure and albumin concentration, but not on total serum protein concentration. Renal transplant in 1 patient restored the binding of both drugs to a value within the normal range. The combination of hypoalbuminemia and hyperbilirubinemia resulted in the greatest impairment to binding for both drugs. It is concluded that patients with uremia, jaundice, hypoalbuminemia, particularly in combination, are sensitive to usual clinical doses of morphine, at least in part, because of decreased binding to plasma proteins.
“…Morphine pharmacokinetics have been assessed in recent studies using both radiolabeled morphine 4 and unlabeled morphine quantitated in blood by radioimmunoassay.2, [17][18][19] Using the immunoassay technique, 16,17 we extended previous studies by assessing the rate and completeness of absorption of intramuscular mor-phine given in usual therapeutic doses. We also studied the pharmacokinetics of high-dose morphine given intravenously to elderly patients with cardiovascular disease undergoing extensive surgical procedures.…”
mentioning
confidence: 99%
“…puncture, at the end of the infusion and at 1, 2, 3,5, 10, 15,30,45 min, 1 hr, 1. 5,2,3,4,6,8,12,18,24,32, and 48 hr following the end of the infusion. Plasma was separated and frozen until the time of assay.…”
The disposition of parenteral morphine was assessed in two pharmacokinetic studies. In Study 1, 10 mg of morphine sulfate was administered by intravenous (IV) infusion, intramuscular (IM) injection, or both, to 8 healthy young adult male volunteers. Plasma morphine concentrations were determined by radioimmunoassay in multiple blood samples drawn after each dose. Mean (+/-SE) kinetic parameters following IV morphine were: volume of distribution (Vd), 3.2 (+/- 0.3) L/kg; elimination half-life (t1/2beta), 2.9 (+/- 0.5) hr; clearance, 14.7 (+/- 0.9) ml/min/kg; extraction ratio, 0.70 (+/- 0.04). After IM morphine, peak plasma levels ranged from 51 to 62 ng/ml and were reached within 20 min of injection. The absorption half-life averaged 7.7 (+/- 1.6) min. Systemic availability was 100% complete. In study 2, 4 elderly male patients (61 to 80 yr of age) received 45 to 80 mg of morphine sulfate IV prior to operative repair of an abdominal aortic aneurysm. Morphine pharmacokinetics were determined as described above. Kinetic variables were Vd, 4.7 (+/- 0.2) L/kg; t1/2beta, 4.5 (+/- 0.3) hr; clearance, 12.4 (+/- 1.2) ml/min/kg; extraction ratio, 0.59 (+/- 0.05). Both studies demonstrate that morphine distribution is rapid and extensive and its t1/2beta relatively short. IM morphine is rapidly and completely absorbed.
“…Recently, the FDA published a proposal regulating irradiated foods for human consumption (2). The proposal permits irradiation of any food at a dose not >lo0 Krads without the additional safety data.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.